Fidelity Investments
RNA icon

Fidelity Investments’s Atrium Therapeutics RNA Stock Holding History

Fidelity Investments’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$463K Buy
55,892
+22,360
+67% +$264K ﹤0.01% 3332
2026
Q2 		$451K Buy
33,532
+4,240
+14% +$55.4K ﹤0.01% 3318
2026
Q1 		$392K Buy
+29,292
New +$412K ﹤0.01% 3219

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return
Landscape Capital Management
Landscape Capital Management Englewood, New Jersey $1.34B AUM 18.69% 1-Year Est. Return

Fidelity Investments's RNA Position: Q3 2026 in Review

Fidelity Investments increased its Atrium Therapeutics (RNA) stake by 67% in Q3 2026, buying an estimated $264K and bringing the position to 55,892 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Fidelity Investments first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. 50 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Fidelity Investments held 55,892 shares of Atrium Therapeutics worth $463K as of Q3 2026.
  • Fidelity Investments bought 22,360 Atrium Therapeutics shares in Q3 2026, an estimated $264K.
  • Atrium Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #3332 holding.
  • Fidelity Investments first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 50 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.